RxDoctor Payments Data

Christiana Brenin, MD

Medical Oncology · Charlottesville, VANPI 1972655934

Payments from drug & device makers

What this record shows

This record is dominated by education: $55 of the $55 with a category attached, or 100.0%. AstraZeneca accounts for 78.4% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for medical oncology clinicians in VA, where the typical reported total is $926.

$55in general payments, 2019–2025

Across 2 payments — averaging $27.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$43
  • Gilead$12
$108,642in research payments, 2019–2025

Across 5 payments — averaging $21,728 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astrazeneca UK Limited$77K
  • GE HealthCare$29K
  • Macrogenics, Inc.$3K

What the payments were for

  • Education$55100%

General payments by program year

21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca1$43
Gilead1$12

How this compares

$55 in reported general payments places this provider in the 15th percentile of 95 medical oncology providers in Virginia.

See all medical oncology providers in Virginia

Medicare billing

Part B allowed, 2024
$54,234
Medicare patients
223
Services billed
684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Exemestane35$4,719
Letrozole92$2,093
Anastrozole30$460
Tamoxifen Citrate14$399
Gabapentin17$192
Dexamethasone14$177
Alendronate Sodium17$133
Prochlorperazine Maleate11$110

Paid to pharmacies, not to this prescriber.

Other medical oncology in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →